Protective effects of avasopasem manganese (GC4419) against sepsis‐induced acute lung injury: A comprehensive experimental study
European Journal of Clinical Investigation · 2026
DOI: 10.1111/eci.70111 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2026. Verfasst von R Peksöz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Atatürk University Research Hospital, Erzurum, Turkey. Hauptthemen laut MEDLINE: Sepsis, Acute Lung Injury, Antioxidants. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Türkiye Sağlık Enstitüleri Başkanlığı (TÜSEB) with Project (program code: 2022-ACİL-11 / A GRUBU ACİL AR-GE PROJE DESTEK PROGRAMI p, Türkiye Sağlık Enstitüleri Başkanlığı.
Themen: Sepsis
Abstract (Originalsprache)
Background
Sepsis is a life‐threatening organ dysfunction caused by a dysregulated host response to infection, characterised by excessive oxidative stress and cytokine release. This study evaluated the protective effects of avasopasem manganese (AVA), a superoxide dismutase mimetic, on sepsis‐induced lung injury in a murine model.
Methods
Sepsis was induced in mice via cecal ligation and puncture (CLP). The study included five groups ( n = 8/group): Sham (control), CLP (Sepsis) and CLP + AVA at doses of 2.5, 5 or 10 mg/kg. Serum and lung tissue samples were analysed for pro‐inflammatory cytokines (tumour necrosis factor α (TNF‐α), interleukin (IL)‐1β, IL‐6), oxidative stress markers (malondialdehyde, MDA) and antioxidant enzyme activity (superoxide dismutase, SOD; glutathione, GSH; catalase, CAT). Quantitative real‐time PCR (qRT‐PCR) assessed cytokine mRNA expression, while histopathological examination evaluated lung tissue damage.
Results
Serum and lung tissue levels of TNF‐α, IL‐1β, IL‐6 and MDA were lowest in the healthy control group and highest in the sepsis group ( p < .001). A significant dose‐dependent decrease in cytokine levels was observed with increasing doses of AVA. Regarding antioxidants, SOD, GSH and CAT enzyme activities were highest in the control group and lowest in the sepsis group ( p < .05). A significant increase in antioxidant enzyme activity was observed with increasing doses of AVA. In molecular analyses, the expression levels of TNF‐α, IL‐1β and IL‐6 were highest in the sepsis group, while relative messenger RNA (mRNA) expression results changed inversely with the drug dosage. Histopathological analyses revealed inflammation, edema and hyaline membrane formation in the sepsis group, whereas increasing doses of the drug showed improvement in lung tissue.
Conclusions
AVA demonstrated a significant protective effect against sepsis‐induced lung injury through its antioxidant and anti‐inflammatory properties. The most effective dose was determined to be 10 mg/kg. These findings suggest the potential use of AVA as an adjunctive agent in sepsis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Atatürk University Research Hospital, Erzurum, Turkey.
- Department of General Surgery, Erzurum City Hospital, Erzurum, Turkey.
- Department of Medical Pharmacology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
- Department of Pathology, Atatürk University, Faculty of Medicine, Erzurum, Turkey.
- Department of Biochemistry, Faculty of Pharmacy, Atatürk University, Erzurum, Turkey.
- Urology, SBU Van Training and Research Hospital, Van, Turkey.
ORCID-Profile: R Peksöz, E Ağırman, T Tavacı, A S Topatan, S Özmen, Z Kutlu, V Atış, Z Halıcı, S S Atamanalp
Förderung
- Türkiye Sağlık Enstitüleri Başkanlığı (TÜSEB) with Project (program code: 2022-ACİL-11 / A GRUBU ACİL AR-GE PROJE DESTEK PROGRAMI p
- Türkiye Sağlık Enstitüleri Başkanlığı
Zitieren
APA
Peksöz, R., Ağırman, E., Tavacı, T., Topatan, A. S., Özmen, S., Kutlu, Z., Atış, V., Halıcı, Z., & Atamanalp, S. S. (2026). Protective effects of avasopasem manganese (GC4419) against sepsis‐induced acute lung injury: A comprehensive experimental study. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70111
Vancouver
Peksöz R, Ağırman E, Tavacı T, Topatan AS, Özmen S, Kutlu Z, et al. Protective effects of avasopasem manganese (GC4419) against sepsis‐induced acute lung injury: A comprehensive experimental study. European Journal of Clinical Investigation. 2026. doi:10.1111/eci.70111
BibTeX
@article{Peksz2026,
author = {Peksöz, R and Ağırman, E and Tavacı, T and Topatan, A S and Özmen, S and Kutlu, Z and Atış, V and Halıcı, Z and Atamanalp, S S},
title = {Protective effects of avasopasem manganese (GC4419) against sepsis‐induced acute lung injury: A comprehensive experimental study},
journal = {European Journal of Clinical Investigation},
year = {2026},
doi = {10.1111/eci.70111}
}
EUVIMED